Liraglutide and lixisenatide — two GLP-1 drugs approved for diabetes — prevented motor impairment and dopamine neuron loss in a mouse model of Parkinson's disease, outperforming the older GLP-1 drug exendin-4.
2 of 3 GLP-1 drugs were neuroprotectiveLiraglutide and lixisenatide preserved dopamine neuron markers and motor function in Parkinson's mice, while exendin-4 did not at the dose tested
What the researchers found
In the MPTP mouse model of Parkinson's disease, 14 days of daily liraglutide (25 nmol/kg) and lixisenatide (10 nmol/kg) treatment prevented:
- Motor impairment on Rotarod, open-field locomotion, and catalepsy tests
- Reduction of tyrosine hydroxylase (TH) levels — the enzyme needed for dopamine production — in the substantia nigra and basal ganglia
- Pro-apoptotic signaling (reduced BAX, increased Bcl-2)
Exendin-4 at 10 nmol/kg showed no protective effects, suggesting the newer, longer-acting GLP-1 drugs have superior neuroprotective properties at comparable doses.
Why it matters
Parkinson's disease has no neuroprotective treatment — current drugs only manage symptoms. GLP-1 drugs are already FDA-approved, well-tolerated, and prescribed to millions for diabetes and weight loss. If they also protect dopamine neurons, they could be repurposed relatively quickly for Parkinson's. This study, combined with a separate pilot clinical trial of exendin-4 in Parkinson's patients showing positive results, built the case for larger human trials that are now underway.
How the study worked
C57BL/6 mice received daily injections of the neurotoxin MPTP (20 mg/kg, intraperitoneally) for 7 days to induce Parkinson's-like dopamine neuron loss. Three GLP-1 drugs were tested with daily intraperitoneal injections for 14 days: exendin-4 (10 nmol/kg), liraglutide (25 nmol/kg), and lixisenatide (10 nmol/kg). Motor function was assessed via Rotarod, open-field locomotion, and catalepsy tests. Brain tissue was analyzed for tyrosine hydroxylase levels and apoptotic signaling molecules (BAX and Bcl-2).
What this study cannot tell us
The MPTP model is a chemical lesion model that only partially replicates human Parkinson's disease — it doesn't produce Lewy bodies or progressive neurodegeneration. The study used a single dose of each drug, so the exendin-4 failure may reflect dose selection rather than true inferiority. The 14-day treatment and short observation period don't address long-term neuroprotection. Sample sizes per group are not specified in the abstract. Intraperitoneal injection is not the clinical route for these drugs.
How to read the evidence
This is a preclinical mouse study using a standard but limited Parkinson's model (MPTP). While the results are consistent with other GLP-1 neuroprotection studies, it remains animal data without direct clinical applicability. Evidence strength is low to moderate.
When this study was published
Published in 2015, this study preceded the large-scale clinical trials of GLP-1 drugs for Parkinson's that are now underway. It remains relevant as foundational evidence supporting those trials.
The bigger picture
This study is part of a wave of research exploring GLP-1 drugs for neurodegenerative diseases. The GLP-1 receptor is expressed in the brain, and these drugs appear to have anti-inflammatory, anti-apoptotic, and neurotrophic properties beyond their metabolic effects. Liraglutide is currently in clinical trials for both Alzheimer's and Parkinson's disease. The finding that newer, longer-acting GLP-1 drugs outperform exendin-4 has important implications for which drugs should be prioritized in human trials.
Questions still open
- Do liraglutide or lixisenatide show neuroprotective effects in human Parkinson's disease clinical trials?
- Would higher doses of exendin-4 match the neuroprotective effects of liraglutide and lixisenatide?
- Is the neuroprotective effect of GLP-1 drugs mediated through the GLP-1 receptor in the brain, or through indirect metabolic improvements?
Common questions
Could drugs like Ozempic protect against Parkinson's disease?
Why did exendin-4 not work in this study when it worked in a Parkinson's clinical trial?
Read the original research
Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
Neuroscience, 303, 42-50
Citation
Liu, W; Jalewa, J; Sharma, M; Li, G; Li, L; Hölscher, C. (2015). Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.. Neuroscience, 303, 42-50. https://doi.org/10.1016/j.neuroscience.2015.06.054